Japanese pharmaceutical company Kyowa Kirin (TYO: 4151) has unveiled plans for a substantial investment of $530 million to construct a state-of-the-art biologics manufacturing facility in the United States. This strategic move is aimed at advancing the development and production of next-generation antibody therapies targeting rare and serious diseases. The facility, encompassing an area of 15,951 square meters, is scheduled to begin construction in the second half of 2024, with an anticipated operational commencement in 2027.
Upon completion, the U.S.-based plant will serve as a hub for supplying products for both clinical trials and commercial distribution, aligning with and augmenting Kyowa Kirin’s existing infrastructure in Japan.- Flcube.com
